Surgical Treatment for Early Stage NSCLC Differs by Race

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 3
Volume 9
Issue 3

A national study of nearly 11,000 patients confirmed what previous regional studies have suggested: Black Americans are less likely than whites to undergo surgery for early stage non-

CHICAGO—A national study of nearly 11,000 patients confirmed what previous regional studies have suggested: Black Americans are less likely than whites to undergo surgery for early stage non-small-cell lung cancer (NSCLC).

The variation in treatment may explain some of the differences in survival that have been observed between blacks and whites, and it indicates that physicians may be able to improve survival of black patients by increasing their rates of surgical therapy, health services researcher Peter Bach, MD, said at the Second Annual Cancer Care Symposium sponsored by the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and others.

Study Results

Dr. Bach and his colleagues at Memorial Sloan-Kettering Cancer Center evaluated the care given to 10,984 Medicare patients identified as having stage I or II NSCLC in the Surveillance Epidemiology and End Results (SEER) database between 1985 and 1993. Analysis of data from this review concluded that race was associated with treatment for early stage NSCLC.

There was a 12.7% absolute difference in the rate of surgery between whites and blacks; a total of 76.7% of white patients had surgery, compared with 64% of black patients. The likelihood that a black patient would have surgery vs a white patient was 0.83, and the odds ratio for a black patient to have surgery, compared with a white patient, was 0.51.

This disparity translated into higher overall mortality for blacks. Overall 5-year survival for the patients in the study was 34% for white patients and 26% for black patients.

There was no statistically significant difference in survival when patients had the same treatment. For patients having surgery, the 5-year survival rate was 43% for white patients and 39% for black patients. White patients who did not undergo surgery had a 5% survival rate at 5 years, compared with 4% for black patients who had nonsurgical care.

“Although there is a large overall difference in survival, there is no apparent survival difference based on treatment. This is good evidence that race does not affect treatment outcome,” he said.

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
Thomas Marron, MD, PhD, presented a session on clinical data that established standards of care for stage II and III lung cancer treatment at CFS 2025.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.